Shuttle Pharmaceuticals (NASDAQ:SHPH) priced a public offering with a health-care focused institutional investor for the purchase and sale of up to ~2.95M shares and warrants to purchase up to ~2.95M shares at a combined offering price of $1.525 per share and accompanying warrant.
The aggregate gross proceeds of approximately $4.5M and assuming no exercise of the warrants. The warrants will have an exercise price of $1.40 per share.
The closing of the offering is expected to occur on or about October 31, 2024.
Net proceeds will be used to fund IND-enabling and Phase I and II clinical trials of product candidates, including $2.3M in payments that will be owed to Theradex Systems.
The stock price dropped 5.6% on Tuesday during after hours of trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.